Consensus Dr. Reddy's Laboratories Limited

Equities

DRREDDY

INE089A01023

Market Closed - Bombay S.E. Other stock markets 06:00:46 2024-04-16 am EDT			5-day change	1st Jan Change
6,052 ^INR	+0.70%		-1.88%	+4.38%

Apr. 10	Dr. Reddy's Launches Migraine Management Device Nerivio in Germany	MT
Apr. 10	Dr. Reddy's Launches Migraine Management Wearable in Germany	MT

Evolution of the average Target Price on Dr. Reddy's Laboratories Limited

Price target over the last 5 years

History of analyst recommendation changes

a0b.YqT_LD4ubxAGdeuXiknxOoGgAT1lc9hdibeAi2lEmow.V-6rRkdsCj1SPYD07DGgT6zPSm0VFpJo2-DM21gj3tYp15ZzWl0gWE0n0w~22a479c4f526c03d309ab97f835eb02d

Analyst Recommendations on Dr. Reddy's Laboratories Limited

Barclays Adjusts Price Target on Dr. Reddy's Laboratories to $80 From $75, Keeps Overweight Rating	Jan. 29	MT
Indian Equities Bounce Back on Thursday Amid Likelihood of US Rate Cuts in US	Jan. 04	MT
Indian Equities Close Higher on Friday as Major Central Banks Hold Rates Steady	Nov. 03	MT
Jefferies Adjusts Dr. Reddy’s Laboratories’ Price Target to INR6,250 From INR6,330, Keeps at Buy	23-10-30	MT
Indian Equities End Lower After US Fed Hints Rates Staying Higher for Longer	23-09-21	MT
Jefferies Adjusts Dr. Reddy Laboratories’ to INR6,300 From INR5,600, Keeps at Buy	23-07-27	MT
Indian Equities Drag as Several Central Banks Hike Interest Rates; Adani Enterprises Slumps 7%	23-06-23	MT
Indian Equites Soar on Friday as Investors Bet on Delay in Further US Rate Hikes	23-06-16	MT
Barclays Adjusts Price Target on Dr. Reddy's Laboratories to $70 From $67, Maintains Overweight Rating	23-06-01	MT
Nomura Adjusts Dr Reddy's Laboratories' Price Target to INR5,161 From INR5,552, Keeps at Buy	23-01-30	MT
Barclays Adjusts Price Target on Dr. Reddy's Laboratories to $66 From $69, Reiterates Overweight Rating	22-10-25	MT
Barclays Adjusts Dr. Reddy's Laboratories' Price Target to $69 from $68, Maintains Overweight Rating	22-09-12	MT
Barclays Lowers Dr. Reddy's Laboratories' Price Target to $68 From $70, Maintains Overweight Rating	22-07-25	MT
Nomura Adjusts Dr. Reddy's Laboratories’ Price Target to 5,552 Indian Rupees From 5,856 Indian Rupees, Keeps at Buy	22-01-31	MT
Barclays Adjusts Price Target on Dr. Reddy's Laboratories to $80 From $78, Maintains Overweight Rating	21-11-01	MT
Nomura Adjusts Dr Reddy's Laboratories' Price Target to 5,856 Indian Rupees From 5,619 Indian Rupees, Keeps at Buy	21-11-01	MT
DR REDDY LABORATORIES : Nomura Adjusts Dr. Reddy's Laboratories' Price Target to 5,619 Indian Rupees From 6,145 Indian Rupees, Keeps at Buy	21-07-29	MT
DR REDDY LABORATORIES' : Price Target From Nomura Raised to INR6,145 From INR5,065, Buy Rating Maintained	21-05-18	MT
DR REDDY LABORATORIES : Nomura Adjusts Dr. Reddy's Laboratories' Price Target to 6,145 Indian Rupees From 5,065 Indian Rupees, Keeps at Buy	21-05-18	MT
Sub: Intimation for withdrawal of Credit Rating (Form 6-K)	21-05-12	PU
Dr Reddy Laboratories : India Ratings & Research Withdraws A1+ Rating on Dr. Reddy's Laboratories' Commercial Paper	21-05-10	MT
Wockhardt : CARE Ratings Gives BBB- Rating on Wockhardt's Proposed Non-Convertible Bonds; Outlook Stable	21-04-07	MT
-ANALYST ACTIONS : Nomura Upgrades Dr. Reddy's Laboratories to Buy From Neutral, Cuts Price Target to INR5,065 From INR5,165	21-03-22	MT
DR REDDY LABORATORIES : Nomura Upgrades Dr Reddy's Laboratories to Buy From Neutral, Adjusts Price Target to 5,065 Indian Rupees From 5,165 Indian Rupees	21-03-22	MT
Axis Bank : Indian shares close at record highs; RBI rate decision awaited	21-02-04	RE